Skip to main content

REVIEW article

Front. Cardiovasc. Med.
Sec. Cardiovascular Genetics and Systems Medicine
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1501735
This article is part of the Research Topic Advancing Cardiovascular Disease Understanding Through Metabolomics and Metabolic Regulation Networks View all 3 articles

Advances of research in diabetic cardiomyopathy: diagnosis and the emerging application of sequencing

Provisionally accepted
Qianqian He Qianqian He 1Ze Lai Ze Lai 2Zhengyao Zhai Zhengyao Zhai 3Beibei Zou Beibei Zou 1Yangkai Shi Yangkai Shi 1Chao Feng Chao Feng 1*
  • 1 Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, China
  • 2 Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
  • 3 Shanghai Cancer Center, Fudan University, Shanghai, Shanghai Municipality, China

The final, formatted version of the article will be published soon.

    Diabetic cardiomyopathy (DCM) is one of the most prevalent and severe complications associated with diabetes mellitus (DM). The onset of DCM is insidious, with the symptoms being obvious only in the late stage. Consequently, the early diagnosis of DCM is a formidable challenge which significantly influences the treatment and prognosis of DCM. Thus, it becomes imperative to uncover innovative approaches to facilitate the prompt identification and diagnosis of DCM. On the traditional clinical side, we tend to use serum biomarkers as well as imaging as the most common means of diagnosing diseases because of their convenience as well as affordability. As we delve deeper into the mechanisms of DCM, a wide variety of biomarkers are becoming competitive diagnostic indicators. Meanwhile, the application of multiple imaging techniques has also made efforts to promote the diagnosis of DCM.Besides, the spurt in sequencing technology has made it possible to give hints about disease diagnosis from the genome as well as the transcriptome, making diagnosis less difficult, more sensitive, and more predictive. Overall, sequencing technology is expected to be the superior choice of plasma biomarkers for detecting lesions at an earlier stage than imaging, and its judicious utilization combined with imaging technologies will lead to a more sensitive diagnosis of DCM in the future. Therefore, this review meticulously consolidates the progress and utilization of various biomarkers, imaging methods, and sequencing technologies in the realm of DCM diagnosis, with the aim of furnishing novel theoretical foundation and guide future research endeavors towards enhancing the diagnostic and therapeutic landscape of DCM.

    Keywords: ：diabetic cardiomyopathy, biomarkers, early diagnosis, Diagnostic Imaging, Inflammatory mediator, Speckle tracking echocardiography, Sequencing

    Received: 25 Sep 2024; Accepted: 27 Dec 2024.

    Copyright: © 2024 He, Lai, Zhai, Zou, Shi and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Chao Feng, Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.